Loading...
Loading...
Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of gross margin.
The trailing-twelve-month gross margin at Biovail Corporation
BVF stands at 73.22%. BVF’s quarterly revenue growth is 26.70% y/y.
The trailing-twelve-month gross margin at Alkermes Inc
ALKS stands at 72.27%. Analysts at Jesup & Lamont initiated coverage of ALKS with a “buy” rating.
The trailing-twelve-month gross margin at Matrixx Initiatives Inc
MTXX stands at 69.27%. GG’s shares fell 3.06% over the past 52 weeks, while the S&P 500 index gained 16.67% in the same period.
The trailing-twelve-month gross margin at Nektar Therapeutics
NKTR stands at 68.97%. NKTR’s quarterly revenue growth is 242.30% y/y.
Trading Ideas.© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Posted In: EarningsLong IdeasMarketsTrading IdeasBiotechnologyDrug Delivery IndustryHealth CareHighest Gross MarginLife Sciences Tools & ServicesPharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in